• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

阿尔茨海默病神经影像学倡议临床核心。

The Alzheimer's Disease Neuroimaging Initiative Clinical Core.

机构信息

Alzheimer's Therapeutic Research Institute, University of Southern California, San Diego, California, USA.

Department of Neurology, Mayo Clinic, Rochester, Minnesota, USA.

出版信息

Alzheimers Dement. 2024 Oct;20(10):7361-7368. doi: 10.1002/alz.14167. Epub 2024 Aug 13.

DOI:10.1002/alz.14167
PMID:39136045
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11485391/
Abstract

The Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical Core is responsible for coordination of all clinical activities at the ADNI sites, including project management, regulatory oversight, and site management and monitoring, as well as the collection of all clinical data and management of all study data. The Clinical Core is also charged with determining the clinical classifications and criteria for enrollment in evolving AD trials and enabling the ongoing characterization of the cross-sectional features and longitudinal trajectories of the ADNI cohorts with application of these findings to optimal clinical trial designs. More than 2400 individuals have been enrolled in the cohorts since the inception of ADNI, facilitating refinement of our understanding of the AD trajectory and allowing academic and industry investigators to model therapeutic trials across the disease spectrum from the presymptomatic stage through dementia. HIGHLIGHTS: Since 2004, the Alzheimer's Disease Neuroimaging Initiative (ADNI) Clinical Core has overseen the enrollment of > 2400 participants with mild cognitive impairment, mild Alzheimer's disease (AD) dementia, and normal cognition. The longitudinal dataset has elucidated the full cognitive and clinical trajectory of AD from its presymptomatic stage through the onset of dementia. The ADNI data have supported the design of most major trials in the field.

摘要

阿尔茨海默病神经影像学倡议 (ADNI) 临床核心负责 ADNI 站点的所有临床活动的协调,包括项目管理、监管监督以及站点管理和监测,以及所有临床数据的收集和所有研究数据的管理。临床核心还负责确定不断发展的 AD 试验的临床分类和纳入标准,并通过将这些发现应用于最佳临床试验设计,使 ADNI 队列的横断面特征和纵向轨迹得到持续描述。自 ADNI 成立以来,已有超过 2400 人入组了这些队列,这有助于我们更深入地了解 AD 的发展轨迹,并使学术和行业研究人员能够对从无症状阶段到痴呆症的整个疾病谱进行治疗试验建模。要点:自 2004 年以来,阿尔茨海默病神经影像学倡议 (ADNI) 临床核心已经监督了超过 2400 名轻度认知障碍、轻度阿尔茨海默病 (AD) 痴呆和认知正常的参与者的入组。纵向数据集阐明了 AD 从无症状阶段到痴呆症发作的完整认知和临床轨迹。ADNI 数据支持了该领域大多数主要试验的设计。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/ca5905dae184/ALZ-20-7361-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/b535eee5d25c/ALZ-20-7361-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/6ee25a2babf7/ALZ-20-7361-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/ca5905dae184/ALZ-20-7361-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/b535eee5d25c/ALZ-20-7361-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/6ee25a2babf7/ALZ-20-7361-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/c111/11485391/ca5905dae184/ALZ-20-7361-g001.jpg

相似文献

1
The Alzheimer's Disease Neuroimaging Initiative Clinical Core.阿尔茨海默病神经影像学倡议临床核心。
Alzheimers Dement. 2024 Oct;20(10):7361-7368. doi: 10.1002/alz.14167. Epub 2024 Aug 13.
2
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.了解疾病进展和改善阿尔茨海默病临床试验:阿尔茨海默病神经影像学倡议的最新重点。
Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13.
3
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.阿尔茨海默病神经影像学倡议:成立以来发表论文的综述。
Alzheimers Dement. 2013 Sep;9(5):e111-94. doi: 10.1016/j.jalz.2013.05.1769. Epub 2013 Aug 7.
4
2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception.阿尔茨海默病神经影像学计划2014年更新:自启动以来发表论文综述
Alzheimers Dement. 2015 Jun;11(6):e1-120. doi: 10.1016/j.jalz.2014.11.001.
5
The Alzheimer's Disease Neuroimaging Initiative: a review of papers published since its inception.阿尔茨海默病神经影像学倡议:成立以来发表论文的回顾。
Alzheimers Dement. 2012 Feb;8(1 Suppl):S1-68. doi: 10.1016/j.jalz.2011.09.172. Epub 2011 Nov 2.
6
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.阿尔茨海默病神经影像学倡议在阿尔茨海默病治疗时代:对 2021 年至 2022 年 ADNI 研究的回顾。
Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12.
7
Harnessing peripheral DNA methylation differences in the Alzheimer's Disease Neuroimaging Initiative (ADNI) to reveal novel biomarkers of disease.利用阿尔茨海默病神经影像学倡议(ADNI)中的外周 DNA 甲基化差异来揭示疾病的新型生物标志物。
Clin Epigenetics. 2020 Jun 15;12(1):84. doi: 10.1186/s13148-020-00864-y.
8
Alzheimer's Disease Neuroimaging Initiative 2 Clinical Core: Progress and plans.阿尔茨海默病神经影像学计划2临床核心:进展与计划。
Alzheimers Dement. 2015 Jul;11(7):734-9. doi: 10.1016/j.jalz.2015.05.005.
9
Longitudinal Exposure-Response Modeling of Multiple Indicators of Alzheimer's Disease Progression.阿尔茨海默病进展多项指标的纵向暴露-反应建模。
J Prev Alzheimers Dis. 2023;10(2):212-222. doi: 10.14283/jpad.2023.13.
10
Lower Serum Calcium as a Potentially Associated Factor for Conversion of Mild Cognitive Impairment to Early Alzheimer's Disease in the Japanese Alzheimer's Disease Neuroimaging Initiative.血清钙水平降低可能与轻度认知障碍向早期阿尔茨海默病转化有关:日本阿尔茨海默病神经影像学倡议研究。
J Alzheimers Dis. 2019;68(2):777-788. doi: 10.3233/JAD-181115.

引用本文的文献

1
Efficacy of extract in amyloid PET-positive patients with mild cognitive impairment.提取物在淀粉样蛋白PET阳性的轻度认知障碍患者中的疗效。
Front Neurol. 2025 Aug 15;16:1639924. doi: 10.3389/fneur.2025.1639924. eCollection 2025.
2
Association of CSF soluble TREM1 levels with hippocampal atrophy in cognitively impaired older adults.认知功能受损老年人脑脊液中可溶性髓系细胞触发受体-1水平与海马萎缩的关系
Front Aging Neurosci. 2025 Jan 14;16:1481526. doi: 10.3389/fnagi.2024.1481526. eCollection 2024.

本文引用的文献

1
A New Framework for Dementia Nomenclature.痴呆症命名的新框架。
JAMA Neurol. 2023 Dec 1;80(12):1364-1370. doi: 10.1001/jamaneurol.2023.3664.
2
The Alzheimer's Disease Neuroimaging Initiative in the era of Alzheimer's disease treatment: A review of ADNI studies from 2021 to 2022.阿尔茨海默病神经影像学倡议在阿尔茨海默病治疗时代:对 2021 年至 2022 年 ADNI 研究的回顾。
Alzheimers Dement. 2024 Jan;20(1):652-694. doi: 10.1002/alz.13449. Epub 2023 Sep 12.
3
Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial.
多奈哌齐治疗早期症状性阿尔茨海默病的随机临床试验。
JAMA. 2023 Aug 8;330(6):512-527. doi: 10.1001/jama.2023.13239.
4
Lecanemab in Early Alzheimer's Disease.早期阿尔茨海默病中的lecanemab
N Engl J Med. 2023 Jan 5;388(1):9-21. doi: 10.1056/NEJMoa2212948. Epub 2022 Nov 29.
5
The AHEAD 3-45 Study: Design of a prevention trial for Alzheimer's disease.AHEAD 3-45 研究:阿尔茨海默病预防试验设计。
Alzheimers Dement. 2023 Apr;19(4):1227-1233. doi: 10.1002/alz.12748. Epub 2022 Aug 15.
6
Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease.两项早期阿尔茨海默病中阿杜卡努单抗的随机 3 期研究。
J Prev Alzheimers Dis. 2022;9(2):197-210. doi: 10.14283/jpad.2022.30.
7
Using the Alzheimer's Disease Neuroimaging Initiative to improve early detection, diagnosis, and treatment of Alzheimer's disease.利用阿尔茨海默病神经影像学倡议改善阿尔茨海默病的早期检测、诊断和治疗。
Alzheimers Dement. 2022 Apr;18(4):824-857. doi: 10.1002/alz.12422. Epub 2021 Sep 28.
8
MCI Criteria in ADNI: Meeting Biological Expectations.ADNI中的轻度认知障碍标准:符合生物学预期。
Neurology. 2021 Sep 20;97(12):597-599. doi: 10.1212/WNL.0000000000012588.
9
Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative.了解疾病进展和改善阿尔茨海默病临床试验:阿尔茨海默病神经影像学倡议的最新重点。
Alzheimers Dement. 2019 Jan;15(1):106-152. doi: 10.1016/j.jalz.2018.08.005. Epub 2018 Oct 13.
10
Association Between Elevated Brain Amyloid and Subsequent Cognitive Decline Among Cognitively Normal Persons.认知正常人群中脑淀粉样蛋白升高与随后认知衰退之间的关联。
JAMA. 2017 Jun 13;317(22):2305-2316. doi: 10.1001/jama.2017.6669.